Vericel to Announce Q2 2024 Financial Results on August 1, 2024
Vericel Corporation, based in CAMBRIDGE, Mass., and listed on NASDAQ under the ticker symbol VCEL, has announced the release of its second-quarter financial results for 2024. The company, which is a prominent figure in the advanced therapies sector focusing on sports medicine and severe burn care, will disclose these results on Thursday, August 1, 2024. Following the announcement, Vericel’s management is set to host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial outcomes and key business highlights.
Interested parties can access the live webcast through the Investor Relations section of Vericel’s website, which can be found at http://investors.vcel.com/events-presentations. It is recommended to visit the site at least 15 minutes before the start time to complete the registration process and download any necessary audio software. Additionally, presentation slides for the conference call will be available on the webcast and within the Investor Relations section of the website. For those who prefer to participate via telephone, a registration link is provided on the website to obtain dial-in details and a personal passcode. A replay of the webcast will be accessible on Vericel's website until August 1, 2025.
Vericel Corporation is renowned for its innovative approach, combining advancements in biology with medical technology to develop a distinctive portfolio of cell therapies and specialty biologics. These products are designed to repair injuries and improve patients' quality of life. The company’s product lineup in the United States includes three major offerings.
The first product, MACI® (autologous cultured chondrocytes on porcine collagen membrane), is an autologous cellularized scaffold indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee in adults, with or without bone involvement. This product leverages the patient's own cells to promote healing and restore function in damaged knee cartilage.
The second product, Epicel® (cultured epidermal autografts), serves as a permanent skin replacement for patients suffering from deep dermal or full-thickness burns covering 30% or more of their total body surface area. Epicel is utilized to treat severe burn injuries, providing a critical solution for extensive skin regeneration.
Vericel also holds the exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product derived from proteolytic enzymes. NexoBrid is specifically indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. This product helps in the crucial early phase of burn care by effectively debriding the burn wound, which is essential for subsequent treatment and recovery.
Vericel’s innovative therapies, including MACI and Epicel, are registered trademarks of the corporation, while NexoBrid is a registered trademark of MediWound Ltd. and is licensed to Vericel Corporation.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
